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Non-viralInefﬁcient cytosolic delivery and vector toxicity contribute to the limited use of antisense oligonucleotides
(ASOs) and siRNA as therapeutics. As anthrax toxin (Atx) accesses the cytosol, the purpose of this study was to
evaluate the potential of disarmed Atx to deliver either ASOs or siRNA. We hypothesized that this delivery strat-
egy would facilitate improved transfection efﬁciency while eliminating the toxicity seen for many vectors due to
membrane destabilization. Atx complex formation with ASOs or siRNA was achieved via the in-frame fusion of
either Saccharomyces cerevisiaeGAL4 orHomo sapien sapien PKR (respectively) to a truncation of Atx lethal factor
(LFn), which were used with Atx protective antigen (PA). Western immunoblotting conﬁrmed the production
of: LFN-GAL4, LFn-PKR and PA which were detected at ~45.9 kDa, ~37 kDa, and ~83 kDa respectively and
small angle neutron scattering conﬁrmed the ability of PA to form an annular structure with a radius of gyration
of 7.0 ± 1.0 nm when placed in serum. In order to form a complex with LFn-GAL4, ASOs were engineered to
contain a double-stranded region, and a cell free in vitro translation assay demonstrated that no loss of antisense
activity above 30 pmol ASO was evident. The in vitro toxicity of both PA:LFn-GAL4:ASO and PA:LFn-PKR:siRNA
complexes was low (IC50 N 100 μg/mL in HeLa and Vero cells) and subcellular fractionation in conjunction
with microscopy conﬁrmed the detection of LFn-GAL4 or LFn-PKR in the cytosol. Syntaxin5 (Synt5) was used
as amodel target gene to determine pharmacological activity. The PA:LFn-GAL4:ASO complexes had transfection
efﬁciency approximately equivalent to Nucleofection® over a variety of ASO concentrations (24 h post-
transfection) and during a 72 h time course. In HeLa cells, at 200 pmol ASO (with PA:LFN-GAL4), 5.4 ± 2.0%
Synt5 expression was evident relative to an untreated control after 24 h. Using 200 pmol ASOs, Nucleofection®
reduced Synt5 expression to 8.1± 2.1% after 24 h. PA:LFn-GAL4:ASO transfection of non- or terminally-differen-
tiated THP-1 cells and Vero cells resulted in 35.2 ± 19.1%, 36.4 ± 1.8% and 22.9 ± 6.9% (respectively) Synt5
expression after treatment with 200 pmol of ASO and demonstrated versatility. Nucleofection® with Stealth
RNAi™ siRNA reduced HeLa Synt5 levels to 4.6 ± 6.1% whereas treatment with the PA:LFn-PKR:siRNA resulted
in 8.5 ± 3.4% Synt5 expression after 24 h (HeLa cells). These studies report for the ﬁrst time an ASO and RNAi
delivery system based upon protein toxin architecture that is devoid of polycations. This system may utilize
regulated membrane back-fusion for the cytosolic delivery of ASOs and siRNA, which would account for the
lack of toxicity observed. High delivery efﬁciency suggests further in vivo evaluation is warranted.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).anthrax toxin; BME, beta-mercaptoethanol; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; E7, early 7;
ain I; GFP, Greenﬂuorescent protein; PKR,Homo sapien sapien protein kinase-R; HPV, humanpapilloma virus; ILVs, intraluminal
associatedmembrane protein 2; LF, lethal factor; MVBs, multivesicular bodies; PEI, poly(ethyleneimine); PNS, post-nuclear su-
erevisiae galactose metabolism DNA binding protein; SANS, small-angle neutron scattering; (si)RNA, small interfering; Synt5,
.C.W. Richardson).
.
. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
317P.D.R. Dyer et al. / Journal of Controlled Release 220 (2015) 316–3281. Introduction
Inefﬁcient cytosolic delivery, suboptimal pharmacokinetics and
pharmacodynamics and vector toxicity contribute to the limited appli-
cation of antisense oligonucleotides (ASOs) and small interfering
(si)RNAs as routinely used clinical tools [1,2]. A variety of non-viral
delivery systems have been explored in relation to the intracellular de-
livery of siRNA and ASOs. However, to date, despite three antisense
drugs being licensed by the FDA [3,4,5], no ASO intracellular delivery
systems have entered into routine clinical use [1,2].
Anthrax toxin (Atx) has evolved to mediate the cytosolic delivery of
macromolecules [6] and the attenuation of its intrinsic toxicity using
recombinant technology is facile i.e. using recombinant PCR to remove
Lethal Factor (LF) domains II–IV to give rise to the truncated protein
LFn [7]. The translocation of LFn into the cytosol requires Bacillus
anthracis protective antigen (PA) and has been described [6–10]. This
operation requires the association of PA with one of its three known
receptors (β1-integrin [11], tumor endothelial marker 8 (TEM8) [12]
or capillary morphogenesis gene-2 (CMG-2) [13], which are almost
ubiquitously expressed in mammals. PA has been reported to form
homoheptamers [6] or homooctamers prior to, or during cell receptor
association [14], which are then trafﬁcked onto the limiting membrane
of intraluminal vesicles (ILVs)withinmultivesicular bodies (MVBs) [8,9,
10]. A pH-driven PA conformational change results in PA membrane
insertion (pre-pore to pore transition) [15] and the translocation of
LFn over the ILV limiting membrane, into the lumen of the ILV. A subse-
quent back-fusion event between the ILV and the limitingmembrane of
the MBV releases LF(n) into the cytosol [8,9,10]. Given that all of the
events culminating in back-fusion and LFn cytosolic release are highly
regulated, it may be possible to exploit these trafﬁcking events for not
only the transport of peptides into the cytosol [16,17,18] but also the
movement of nucleic acids,without the aid of any polycationic condens-
ing agents [19,20,21].
Consequently, the aim of this study was to evaluate the potential
of Atx components to deliver ASOs and siRNA to the cytosol without
generating the toxicity resulting from non-speciﬁc membraneFig. 1.Exploitingmembraneback-fusion for thedelivery of ASOs and siRNA. This cartoon is adap
study it is used to illustrate the possible route taken to the cytosol by the Atx derived deliverydestabilization common to many forms of non-viral delivery technolo-
gy. A cartoon representing the proposed delivery strategy, and the
membrane back-fusion event acting as an “airlock” into the cytosol, is
shown (Fig. 1) and is based upon the trafﬁcking of LF [8,9,10]. To this
end, ASOs or siRNA was joined to LFn via the in-frame fusion of a DNA
or RNA binding protein requiring Saccharomyces cerevisiae galactose
metabolismDNAbindingprotein (GAL4) (for ASOs) [21] orHomo sapien
sapien protein kinase-R (PKR) [22] (for RNA) to be fused in frame to LFn
and used in conjunction with PA.
For the ﬁrst time, we report the ability of disarmed Atx to deliver
ASOs and siRNA to a variety of primate cell lines (HeLa, THP-1 and
Vero) without the aid of any polycationic or lipidic helpers. The PA,
LFn-GAL4, LFn-PKR proteins and their complexes with ASO and Stealth
RNAi™ siRNA were characterized in relation to structure and general
toxicity inHela andVero cells in vitro. Fluorescencemicroscopy and sub-
cellular fractionation were used to verify cytosolic entry of LFn-GAL4
and LFn-PKR or their Texas Red®-labeled analogues and the trafﬁcking
of PA to lysobisphosphatidic acid (LBPA) positive endocytic vesicles
over time. Finally the ability of the disarmed Atx to deliver ASOs and
siRNA to a variety of primate cell lines (HeLa, THP-1 and Vero) was
studied by measuring the knockdown of Syntaxin5 (Synt5) expression
as a model to quantitate pharmacological activity in relation to
Nucleofection® (and lipofection) as a benchmark available commercial-
ly to anyone wishing to gauge the efﬁciency of their system in relation
to the data reported herein.2. Materials and methods
2.1. Oligonucleotides
ASOs are described (Table 1) and were supplied by Invitrogen
(Paisley, UK). The antisense sequence against Synt5 has previously
been published [23]. Synt5 speciﬁc Stealth RNAi™ siRNA modiﬁed
RNA (4392420; Life Technologies, Paisley, UK) was purchased
commercially.ted fromdata describing the cytosolic translocation of LF(n) [6–10]. For thepurposes of this
systems described herein i.e. PA:LFn-GAL4:ASO or PA:LFn-PKR:siRNA.
Table 1
ASO targets and sequence.
ASO Target
Forward Snyt5 5′-FFZ ZZE ZZZ EZZ EFE EOZ FAT GCA TGC CGG CAT CAG AGC
AGC CGG CAT
Reverse Snyt5 5′-FFZ ZZE ZZZ EZZ EFE EOZ FAT GCA TGC CGG CTG CTC TGA
TGC CGG CAT
Forward tGFP 5′-EEZ EOZ OZZ OFZ OZZ EZZ EEZ ATG CAT GCC GGC TGC TCT
GAT GCC GGC AT
Reverse tGFP 5′-EEZ EOZ OZZ OFZ OZZ EZZ EEZ ATG CCG GCA TCA GAG CAG
CCG GCA TGC AT
Forward tGFP 5′-GGT GCT CTT CAT CTT GTT GGA
Forward HPV
E7
5′-EEZ OEZ OZE OZE FEO ZZZ OZA TGC ATG CCG GCT GCT CTG
ATG CCG GCA T
Reverse HPV
E7
5′-EEZ OEZ OZE OZE FEO ZZZ OZA TGC ATG CCG GCA TCA GAG
CAG CCG GCA T
After phosphorothioate modiﬁcation: A = F, T = Z, C = O and G = E.
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The DNA sequences coding for the protein LFn-GAL4 and PA83
(based upon GenBank accession numbers: (LFn) AAY15237, (GAL4)
Z73604.1, (PA) AAF86457 and AAT98414) have been previously
described [21]. LFn-PKR was synthesized by BioBasic Inc., (Ontario,
Canada) using the GenBank accession number AAY15237 and
NM_002759 (for PKR). The open reading frame coding for LFn-GAL4
or LFn-PKR was sub-cloned into the bacterial expression cassette
pET151/D (Invitrogen, Paisley, UK). The addition of a V5 epitope tag
and a 6× histidine afﬁnity tag allowed immunodetection and afﬁnity
puriﬁcation from bacterial lysate. LFn-GAL4, LFn-PKR or PA83 were
enriched from cultures of Escherichia coliwith a yield of approximately
2 mg/L using chemically competent E. coli BL21*DE3pLys (Invitrogen,
Paisley, UK) transformed with 10 ng of plasmid and cultured overnight
in 2xYT containing 200 μg/mL ampicillin (Sigma, Dorset, UK) and then
grown in 1000 mL of 2xYT at 37 °C and 200 rpm for 3 h. Subsequently,
isopropylthio-β-galactoside (Sigma, Dorset, UK) was added to a ﬁnal
concentration of 1 mM and incubated for a further 2 h. Bacterial pellets
prepared by centrifugation (6 000×g for 10 min at 4 °C) were lysed
using a French Press (Thermo Scientiﬁc, Paisley, UK) set to 15 000 psi.
Lysateswere cleared (18 000×g for 30min at 4 °C) and the supernatant
passed over a 6× histidine afﬁnity chromatography column (Talon®
resin; Clontech, Saint-Germain-en-Laye, France). The 6×His containing
proteins were eluted using 150 mM imidazole (Sigma, Dorset, UK) in
PBS, in fractions of 1 mL. Protein fractions were analyzed for purity
and concentration, pooled, and dialyzed to exhaustion against PBS
then ﬁlter sterilized (0.22 μm ﬁlter). The ﬁnal protein preparation was
evaluated by SDS-PAGE and subjected to Coomassie staining (to deter-
mine purity) andWestern blot analysis using the antibodies described.2.3. Protein:nucleic acid complex formation
The hybridization of oligonucleotides with LFn-GAL4 has been de-
scribed previously [21]. The PA:LFn-GAL4:ASO complex was assembled
as follows: ﬁrst, two partially complementary oligonucleotides, each
encoding one strand of a GAL4 recognition sequence, were annealed
to form a double-stranded (GAL4) binding sequence with ﬂanking
(single-stranded) antisense sequences. Antisense oligonucleotide
hybridization was performed by repeatedly (×10) melting (1 min at
94 °C), and re-annealing (1 min at 55 °C), the two partially overlapping
oligonucleotides after an initial 2min step at 94 °C. This ASO hybrid was
then introduced to 20 μg/mL LFn-GAL4 and 50 μg/mL PA83 and this
left for 30 min at room temperature to self-assemble. The PA:LFn-
PKR:siRNA complex was assembled in an identical manner to the
PA:LFn-GAL4:ASO complex substituting sterilized LFn-PKR for LFn-
GAL4 and the Stealth RNAi™ siRNA speciﬁc for Synt5 for the annealed
ASOs. Texas Red®-labeling of LFn-GAL4 and LFn-PKR was performedas previously described for bovine serum albumin [24]. Typically less
than 5% (w/v) free Texas Red®was found in the salted exchanged prep-
aration. LFn-GFP was produced as previously described [25].
2.4. Cell culture
The culture and passage of HeLa (ATCC: CCL2), Vero (E6; ATCC: CRL-
1568) and THP-1 (ATCC: TIB-202) cells were described by the supplier.
THP-1 cells were subject to terminal differentiation by adding 320 nM
phorbol 12-myristate 13-acetate (Sigma, Dorset, UK) 24 h prior to the
transfection experiments. Where undifferentiated THP-1 cells were
used the cells were treated as if they were in suspension. Cells were
routinely maintained at 37 °C in 5% (v/v) CO2.
2.5. In vitro toxicity
The PA:LFn-GAL4:ASO and PA:LFn-PRK:siRNA complexes and their
components were tested for toxicity in relation to poly(ethyleneimine)
(PEI) (Sigma, Dorset, UK) using 3-(4,5-dimethylthiazol-2-yl)-2,5-di-
phenyltetrazolium bromide (MTT) (Sigma, Dorset, UK). IC50 values
were calculated using Prism 6.0 (GraphPad software Inc., Ca, USA).
This methodology has been previously described [26].
2.6. Transfection experiments
The PA:LFn-GAL4:ASO or PA:LFn-PKR:siRNA complex containing,
serum-free cell culture media (2 mL) was added to cells seeded at
5 × 105 cells/well 18 h previously, incubated at 37 °C for 240 min
prior to being replaced with complete media. Analysis of target gene
expression was performed by removing the cell culture media, washing
the cells 3 times in PBS and dissolving the monolayer in 100 μL of
Laemmli sample buffer containing 10% (v/v) beta-mercaptoethanol
(BME). HeLa cells were subject to Nucleofection®, using a Nucleofector®
2b (Lonza, Slough, UK) and a volume of 0.1 mL. In the instance of HeLa
cells, the high efﬁciency program I-013was selected andNucleofection®
kit Rwas usedwith 5 × 105 cells. TheNucleofection® of undifferentiated
THP-1 cells was performed using the high viability Nucleofector® pro-
gram U-001 and Nucleofector® kit V (Lonza, Slough, UK), as when the
high efﬁciency program (V-001; Lonza, Slough, UK) was used, cell
death prevented the acquisition of data. Vero cells were subject to
Nucleofection® using program (V-001) and kit V. HPV E7 was detect-
ed by Western immunoblotting as before, using an HPV18 E7-
speciﬁcmonoclonal primary antibody (ab100953; AbCam; Cambridge
UK, used at a dilution of 1:1000) and an HRP-conjugated anti-mouse
secondary (NA931; GE Healthcare; Bucks, UK; used 1:1000).
Oligofectamine® (Life Technologies, Paisley, UK) was used with the
stated quantity of ASO as per the manufacturer's instructions. Simi-
larly sham-transfection experiments with Lipofectamine® were per-
formed with 1 μg pGST-GFP, a plasmid containing no mammalian
promoter [27] and 5 μg of Lipofectamine® (Invitrogen, Paisley, UK)
as per the manufacturer's instructions.
2.7. Western blotting and immunodetection
Western blotting was performed using the Mini-PROTEAN® Tetra
Cell and electroblotting system (BioRad, Hercules, CA, USA) following
the manufacturer's instructions. Typically, 12% (w/v) acrylamide con-
taining resolving gels were used and transfer was conducted at
400 mA for 60 min. All antibodies were diluted into PBS containing
0.01% (v/v) TWEEN20 (Sigma, Dorset, UK) and 5% (w/v) non-fat dried
milk (Marvel, Premier Foods plc, St. Albans, UK). Blocking steps were
performed for 60min shaking at 37 °C using the antibody diluting buff-
er. Antibody hybridizations were performed at 60 min shaking at 37 °C
in a volume of 3 mL. Between the blocking steps and after antibody
hybridization, three PBS (containing 0.01% (v/v) TWEEN20) washes
were performed (5 min at room temperature with gentle shaking).
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only. Detection was performed using pico-stable ECL reagent (Thermo
Scientiﬁc, Paisley, UK) and X-ray ﬁlm (Kodak, Rochester, NY, USA)
following the manufacturer's instructions. Exposed X-ray ﬁlm was de-
veloped, scanned and analyzed using NIH ImageJ, before normalizing
the expression level of the target gene to that of a housekeeper (early
endosomal antigen 1 (EEA1)), detected using a monoclonal anti-EEA1
primary antibody (610456; BD Bioscience; Oxford, UK) at a dilution of
1:1000. As before an anti-mouse HRP-conjugated secondary was used
to detect the primary anti-EEA1 antibody. Care was taken to not exceed
the dynamic range of the detection system. Synt5 expression was de-
tected using a rabbit polyclonal Synt5-speciﬁc primary (13259648;
Thermo Scientiﬁc; Paisley, UK) and an anti-rabbit-speciﬁc, HRP-
conjugated secondary antibody (NA934v; GE Healthcare; (Bucks, UK))
diluted 1:1000. The immunodetection of PA was performed using a
rabbit anti-PA83 primary antibody (ab13808; AbCam; Cambridge, UK,
diluted 1:1000), and an anti-rabbit-HRP-conjugated secondary anti-
body as before. LFn-GAL4 (or LFN-PKR) was immunodetected using a
monoclonal anti-V5 primary antibody (ab13808; AbCam; Cambridge,
UK, diluted 1:1000) with an anti-mouse-HPR-conjugated secondary as
before. For Western blotting and immunodetection typically 100 ng
for recombinant protein was used as a reference.Fig. 2. Characterization of LFn-GAL4 & LFn-PKR, PA83 and ASOs used herein. Here PA:LFn-GAL4
(PA83, LFn-GAL4 and LFn-PKR) and (ii) SANS (PA) (b).Western blotting and immunodetection
SANS was performed by assessing the ability of recombinant, deuterated PA63 (i.e. “activated” P
circles). An IVT kitwas usedmeasuring the inhibition of tGFP expression relative to the addition
for tGFP, one strand of the hybrid described (closed square), the ASO hybrid described (open circ
(c). For all of the antisense treatments described, equal numbers of antisense sequence were u2.8. SANS and data analysis
Deuterated PA83 protein was grown in 2xYT containing 50% (v/v)
deuterium oxide (Sigma, Dorset, UK) and was subject to isolation and
puriﬁcation as before. Proteolytic cleavage was performed using 1 μL
trypsin (0.025% (w/v) trypsin and 0.01% (w/v) EDTA) (Invitrogen,
Paisley, UK) in PBS per mg of deuterated PA83. The PA digest was left
for 20 min at room temperature to produce deuterated PA63. The reac-
tionwas stoppedby adding an excess of Complete™ EDTA-free protease
inhibitor cocktail (Roche, BurgessHill, UK). The liberated PA20 fragment
was removed by afﬁnity chromatography as before. LFn-GFPwas added
to excess aswell as fetal bovine serum (FBS) (Invitrogen, Paisley, UK), to
a ﬁnal concentration of 50% (v/v) FBS, giving a ﬁnal concentration of
1 mg/mL deuterated PA63. This was in contrast to the deuterated
PA63 thatwas diluted to 1mg/mL in PBS. Bothpreparationswere placed
into separate “banjo” cuvettes (Hellma, Essex, UK). The SANS measure-
ments were performed on the ﬁxed-geometry, time-of-ﬂight LOQ
diffractometer (ISIS Spallation Neutron Source, Oxfordshire, UK). All
measurements were carried out at 25 °C. Experimental measuring
times were approximately 80 min. All scattering data were normalized
for the sample transmission and incident wavelength distribution, as
well as corrected for instrumental and sample backgrounds using aand PA:LFn-PKR components were characterized by both: (i) Western blotting (a, inset)
revealed the enrichedproteins to be of the predictedmolecularweight. Characterization by
A83) to form oligomers in either 50% (v/v) fetal bovine serum (open circles) or PBS (black
of a negative control (PBS). The inhibitionmediated by; a 21merASO (closed circle) speciﬁc
le), and theASO hybrid described (Fig. 1a)mixedwith LFn-GAL4 (open square) are shown
sed.
Fig. 3. In vitro toxicity. The effects of the PA:LFn-GAL4:ASO upon HeLa cell viability over 24 (circles), 48 (squares) and 72 h (triangles) were recorded using the MTT assay (a). PA:LFn-
PRK:siRNA in vitro toxicity is also shown (b) and was conducted as previously described (a) substituting LFn-GAL4 for LFn-PKR. Sub-lethal toxicity was investigated using sham transfec-
tions (Lipofectamine®), PBS or PA:LFn-GAL4:ASO treated Vero cells. The appearance of hyper-fused, swollen late endocytic structures (arrows) denoted sub-lethal toxicity (c). The
concentrations used were those required for robust transfection.
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efﬁciency of the detector response. The data were put onto an absolute
scale using a well-characterized partially deuterated polystyrene-blend
standard sample. The scattering pattern was analyzed as a Guinier rep-
resentation (the logarithm of the intensity versus the square of the
wavevector, ln I(Q) vs. Q2), from which a shape-independent radius of
gyration was obtained from the initial linear portion of the decay via
its slope (−Rg2/3). The data describing dPA63 in serum was in agree-
ment with the PA83 derived multimers documented in the protein
data bank (PDB accession 1TZN). As various inﬂexia in this representa-
tion of the data were indicative of non-Gaussian statistics, the data was
recast in a Kratky plot, namely Q2. I(Q) vs. Q, which removed any
Gaussian-like coil (Q−2) dependence.Table 2
In vitro toxicity after 72 h (IC50 (μg/mL; n = 6 ± SEM).
HeLa cells Vero cells
25 kDa branched PEI 2.9 ± 0.6 7.3 ± 0.1
0.8 kDa branched PEI 2.4 ± 0.2 7.4 ± 0.3
20 kDa linear PEI 3.0 ± 0.1 6.9 ± 0.5
ASO 100+ 100+
PA 100+ 100+
LFn-GAL4 100+ 100+
LFn-PKR 100+ 100+
PA:LFn-GAL4:ASO 100+ 100+
PA:LFn-PKR:siRNA 100+ 100+2.9. In vitro translation (IVT) assay
Control reactions were performed using a 1-step human high-yield
mini in vitro translation (IVT) kit (Thermo Scientiﬁc, Paisley, UK) in con-
junction with a control plasmid encoding the protein turbo (t)GFP
(Evrogen; Cambridge Bioscience, Cambridge, UK), in 5 μL volumes, incu-
bated for 3 h at 30 °C. The expression of tGFP was monitored byWestern
immunoblotting using a mouse anti-6His monoclonal primary antibody
(631212; Clontech, Saint-Germain-en-Laye, France, at a 1:1000 dilution)
and an anti-mouse-HPR-conjugated secondary as before. Various ASO
compositions (as described)were added to the reaction at the concentra-
tions given at the beginning of the 3 h incubation period.
2.10. Microscopy and subcellular fractionation
Fractionation experiments were seeded at 1 × 106 cells/150 mm2
dish and two sub-conﬂuent (~90%) dishes were used per treatment.
Treatments consisted of 5 mL serum free media containing 50 μg PA
protein and 50 μg of either LFn-GAL4 or LFn-PKR (/mL), which was
placed under standard incubating conditions. After 4 h the cells were
washed 3 times with PBS and scraped into a 100 μL volume of PBS
containing 5× Complete™ EDTA-free protease inhibitor cocktail
(Roche, Burgess Hill, UK) and lysed by passage through a 21-gauge
needle (×10). Whole cells were then removed by centrifugation
(600 ×g for 1min. at 4 °C) and a post-nuclear supernatant (PNS) gener-
ated by further centrifugation (4000 ×g for 2 min. at 4 °C). Membrane
(pellet) and cytosol (supernatant) were then separated by subjecting
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brane and cytosol fractions were then adjusted to 100 μL total volume
using Lamellae sample buffer containing 20% (v/v) BME. The fractions
were analyzed using the following primary antibodies: α-LDH (L7016;
Sigma; Dorset, UK), as a cytosolic marker, α-V5 (ab9116; AbCam;
Cambridge, UK) to detect either LFn-PKR or LFn-GAL4 and an α-
transferrin receptor (TfR) primary (612124; BD-Transduction labs;
Oxford, UK), was used to detect the presence of the transferrin receptor,
a marker for cell membrane. Microscopy was performed after seeding
1 × 105 Vero cells onto a sterile coverslip and incubating the cells
overnight in complete media. The following day PA was added to the
cells to a ﬁnal concentration of 50 μg/mL aswell as either Texas Red®-la-
beled LFn-PKR or LFn-GAL4 at a concentration of 50 μg/mL in serum free
media. After 4 h the cells were ﬁxed using formalin [24]. Antibodies spe-
ciﬁc for EEA1 (E41120; BD-Transduction labs; Oxford, UK)were used as
a counter immunostain and were used at a dilution of 1:500. EEA1-
speciﬁc primary antibodies were detected using a 1:500 dilution of
Alexa488-conjugated goat anti-mouse speciﬁc secondary antibodies
(A11001; Invitrogen, Paisley, UK). Sub-lethal toxicity experiments were
performed by seeding Vero cells as before and the following
day conducting transfection experiments using the preparations as
described. After 4 h the cells were ﬁxed using cold methanol [24]
and immunostained using an anti- lysosome associated membrane
protein 2 (LAMP2) speciﬁc antibody at a dilution of 1:10 (H4B4; DHSB,
University of Iowa, IA, USA). This primary antibody was detected using a
1:500 dilution of an anti-mouse Texas Red®-labeled secondary (T-862;Fig. 4. PA mediated LFn-GAL4 or LFN-PKR cytosolic translocation by subcellular fractionation. V
documented and show the detection of LFn-GAL4 (containing an N-terminal V5-epitope) in bot
within the cytosolic fractions derived from this methodology was recorded over time (b). Omi
demonstrating speciﬁcity. The cytosolic trafﬁcking of PA:LFn-PKR:ASOwas alsomeasured by co
LFn-GAL4. LFn-PKR also contained an N-terminal V5-epitope.Invitrogen, Paisley, UK). PA localization to LBPA positive endocytic
vesicles was undertaken by pulsing Vero cells with PA (50 μg/mL)
with 200 μM Leupeptin 4 or 8 h prior to ﬁxing the cells with 2%
formalin (w/v) and then processed as previously described [24].
Immunodetection was performed using both (rabbit) α-PA (ab13808;
AbCam; Cambridge) and (mouse) α-LBPA antibodies (clone 6C4,
α-LBPA antibody; Merck Millipore, Watford, UK). Texas Red-conjugated
anti-rabbit and Alex488-conjugated anti-mouse secondary antibodies
were used to visualize both LBPA and PA.
Cells were imaged using an Eclipse 90i overhead ﬂuorescent micro-
scope (Nikon, Japan), using a Nikon Digital Camera (DS-Qi1Nc). The
objective used in imaging was an oil immersion CFI Plan Apochromat
VC 60XN2 (NA 1.4 WD 0.13 mm) (Nikon, Japan).
3. Results
3.1. Characterization of LFn-GAL4 & LFn-PKR, PA83 and ASOs
A cartoon depicting the LFN-GAL4:ASO complex, the LFn-PKR:siRNA
complex and the PA monomer are shown (Fig. 2a). Inset are Western
blots where LFn-GAL4 (~45.9 kDa), LFn-PKR (~37 kDa) and PA
(~83 kDa) were detected at their predicted molecular weights.
Further characterization of the PA component of this system
was conducted by SANS, and showed PA63 (i.e. activated PA83)
oligomerizing in serum (Fig. 2b) [6]. Analysis of the SANS data plotted
as a Guinier representation allowed the derivation of shape-independentero subcellular fractionations derived from cells exposed to PA:LFn-GAL4:ASO have been
h themembrane and cytosolic fractions, after 4 h (a). The temporal residence of FLn-GAL4
tting PA prevented the cytosolic translocation of LFn-GAL4 as did keeping the cells at 0 °C
nducting subcellular fractionation (b) as previously described (a), substituting LFn-PKR for
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and Rg serum = 7.0 ± 1.0 nm (data not shown). The absence of highly
extended structure (Q−1 dependence), was also demonstrated by the
decaying (rather than increasing) background and the almost oscillato-
ry nature of the data was indicative of highly non-Gaussian structures.
Peaks present in the Kratky plot resulting from the scattering from
dPA63 in PBS and in serum (Fig. 2b) reported peaks shifting to smaller
Q (serum), indicating a slightly larger annular structure [28], in agree-
ment with previously published descriptions of PA heptamer [6].
By noting that the peak positions Qmax = 2π/L correlate to distances
L = 14.0 nm in serum and 6.0 nm in PBS, it is likely that in PBS, the
majority of the oligomers contain less than 7 members. For reasons of
clarity and narration, PA heptamers or octamers have been depicted
here (Figs. 1 & 2) as a blue “mushroom”. A more concise description
of this annular structure has been recently published [6].
Further characterization was conducted by examining the effect of
ASO conﬁguration and the presence of LFn-GAL4 upon antisense activity
using a cell-free in vitro translation assay (1-step human high-yield mini
in vitro translation (IVT) kit; Thermo Scientiﬁc, Paisley, UK) (Fig. 2c).
Here, the inhibition of tGFP expression was measured relative to theFig. 5. Evaluation PAmediated LFn-GAL4 or LFN-PKR cytosolic translocation by ﬂuorescencemic
nebulous hazewithin both cortical and non-cortical regions of the cell. These cells were counter
Red®-labeled LFn-GAL4 was still detected within EEA1 positive puncta (size bar is 10 μM). Sim
labeled LFn-GAL4 for Texas Red®-labeled LFn-PKR (b). The localization of PA with LBPA is showaddition of a negative control (PBS), a positive control (a 21mer ASO spe-
ciﬁc for tGFP), one strand of the hybrid ASO, the ASO hybrid described, or
the hybrid describedmixedwith LFn-GAL4. Above 30 pmol of ASO, equiv-
ocal inhibition was observed between all of the materials tested (Fig. 2c).
3.2. In vitro toxicity
An investigation into the effects of the PA:LFn-GAL4:ASO and
PA:LFn-PKR:ASO complex upon HeLa cell viability over 24, 48 and
72 h as measured using the MTT assay [26] was conducted (Fig. 3a & b
respectively). The data describe both complexes exerting little toxicity
over 72 h in vitro relative to PEI (Table 2). These data were reinforced
morphologically using microscopy (Fig. 3c), examining cells decorated
with a primary antibody speciﬁc for the late endocytic marker LAMP2
(denoting late endosomes and lysosomes), visualized using an
AlexFluor488®-labeled secondary antibody. It is of note that after treat-
ment with PBS or the PA:LFn-GAL4:ASO complex, the majority of
LAMP2 positive structures exist as discreet puncta. However, after
sham transfection using Lipofectamine®, hyper-fuzed, clustered
LAMP2 positive structures (lysosomes) are evident (arrows) which mayroscopy. The cytosolic translocation of Texas Red®-labeled LFn-GAL4 (a) was recorded as a
immunostainedwith an antibody speciﬁc for EEA1, (early endosomes) and after 4 h, Texas
ilar observations were made when the experiment was repeated substituting Texas Red®-
n at 4 h and 8 h (c & d respectably) in Vero cells.
Fig. 5 (continued).
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centrations chosenwere representative of those necessary to perform ro-
bust transfection. In an attempt to quantify these microscopic data, 10
randomly selected vesicles were selected from the microtubule-
organizing center (the juxtanuclear region with the highest population
of vesicles) and their diameters at their widest point measured. The
cells exposed to PBS had a mean diameter of 623.5 ± 224.5 nmwhereas
the cells exposed to PA:LFn-GAL4:ASO had a mean diameter of 688.0 ±
250.7 nm. This was in contrast the cells exposed to the liposectamine
lipoplex which had a diameter of 2300.5 ± 1505.2 nm.
3.3. PA mediated LFn-GAL4 or LFn-PKR cytosolic translocation assayed by
subcellular fractionation
The activity of the proteinaceous elements of the complexes de-
scribed was evaluated by assessing the recombinant system's ability to
access the cytosol using both subcellular fractionation (Fig. 4) and mi-
croscopy (Fig. 5). A 4 h incubation with 50 μg/mL PA resulted in a
proportion of a 50 μg/mL dose of LFn-GAL4 (~100 ng, estimated by com-
paring the V5 signal in the cytosol with the proportion of the input rel-
ative to the dose) being detected in an LDH-positive (crude cytosolic)
compartment that did not contain any detectable TfR (the membrane
marker) (Fig. 4a) as well as in a membrane fraction (containing no
LDH). This investigation was continued over time and demonstrated
that both PA and a temperature of 37 °C (as opposed to 0 °C) were nec-
essary for the translocation of LFn-GAL4 in the cytosol of Vero cells
(after 4 h incubation) and that beyond 4 h, the detectable levels of
LFn-GAL4 decline over a 40 h period (Fig. 4b). The ability of the
PA:LFn-PKR complex to provide LFn-PKR with access to the cytosol
was investigated (Fig. 4c). Although these data show that LDH (the cy-
tosolic marker) was detectable in the membrane fraction, this observa-
tion doesn't detract from the observation that similar to LFn-GAL4(Fig. 4a), LFn-PKR is detectable in an LDH fraction devoid of contamina-
tion by the membrane marker (TfR) after an incubation time of 4 h
(Fig. 4c).
3.4. Evaluation PA mediated LFn-GAL4 or LFN-PKR cytosolic translocation
by ﬂuorescence microscopy
A second string of evidence was tested to reinforce the conclusions
drawn from the subcellular fractionation as, if the cytosolic transloca-
tion of LFn-GA:4 or LFn-PKRwas occurring as described, itmight be pos-
sible to visualize these phenomena using a single cell assay. After
incubation with PA, the visualization of Texas Red®-labeled LFn-GAL4
was documented as an intracellular nebulous haze and within EEA1-
positive puncta (i.e. early endosomes) in Vero cells (Fig. 5a). It was of
note that although a ﬂuid phase marker such as Texas Red®-labeled
Dextran or BSA will pass through an EEA1 positive compartment rela-
tively quickly i.e. 5–10 min [24], here, Texas Red®-labeled LFn-GAL4
was readily identiﬁable in an EEA1 positive compartment (i.e. co-
localizing with EEA1) after 4 h. This may indicate that a fraction of
the Texas Red®-labeled LFn-GAL4 remained associated with receptor
associated PA.
Common questions raised by this methodology such as the non-
speciﬁc membrane association of ﬂuorophore and the stability of the
Texas Red®-labeling giving rise to false positive data sets were
controlled for in the previous experiment, conﬁrming the presence of
the protein in the cytosol over a similar time span using not only a dif-
ferent detection system but also a completely separate experimental
methodology. The possibility of the release of the ﬂuorophore (i.e. the
stability of Texas Red®-labeled LFn-GAL4) was addressed in Supple-
mental Fig. 1, which describes a very different (reticular) staining
pattern (relative to Fig. 5) evident when a protein labeled with Texas
Red® is chased into the endolysosome without a protease inhibitor. To
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PA, a second experimentwas undertaken. This resulted in a second form
of experimental evidence documenting Texas Red®-LFn-PKR in the cy-
tosol of Vero cells using ﬂuorescence microscopy (Fig. 5b) against an
EEA1 counter stain. With morphology similar to Texas Red®-labeled
LFn-GAL4 (Fig. 5a), Texas Red®-labeled LFn-PKRwas also detected ubiq-
uitously within the cells (Fig. 5b).
Supplemental Fig. 2 further controls for the possibility that the red
signal detected in Fig. 5 was autoﬂuorescence, documenting an increase
and then decreasing in red signal from Texas Red-labeled LFn-GAL4
over time in live cells. Fig. 5c & d further control of red cytosolic autoﬂu-
orescence in ﬁxed cells as well as demonstrate that after 4 h a limited
amount of co-localization can been seen between a pulse of PA and
LBPA (a marker for MVBs and a lipid critical for back-fusion [9]). After
an additional 4 h a substantially higher degree of co-localization
between PA and LBPA can be observed (Fig. 5d).
3.5. PA:LFn-GAL4:ASO antisense activity against a panel of primate cells
An initial experiment was preformed to evaluate the baseline level
of ASO activity in HeLa cells. Here 200 pmol of ASO (or separately
siRNA) was added to serum free cell culture media, whichwas replaced
by complete media after 4 h. After 24 h a statistically signiﬁcant varia-
tion in target gene expression was evident relative to a PBS treated
control (Supplemental Fig. 3 and supplemental Table 1), where base-
lines of 71.3% and 69.0% Synt5 expression were recorded for cells treat-
ed with only ASO or siRNA respectively.
Having established background levels of ASO transfection (Supple-
mental Fig. 3 and Supplemental Table 1), the effect of increasing
amounts of ASO in concert with static concentrations of PA:LFn-GAL4Fig. 6. PA:LFn-GAL4:ASO antisense activity against a panel of primate cells. Transfections were
PA:LFn-GAL4:ASO complex (a) and were normalized to the expression of EEA1. The level of Sy
igonucleotide (bars containing large squares); 3) Nucleofection® (solid black bars); 4) the PA
(horizontal hatching) are shown. P values showing statistically signiﬁcant down-regulation
50 pmol ASO (b0.0001), 100 pmol ASO (b0.0001) and 200 pmol of ASO (b0.0001) and for N
(b0.0001). The duration of the antisense effect was investigated (b) in HeLa cells where 200 p
point, signiﬁcant down-regulation of Synt5 was documented (for the PA:LFn-GAL4:ASO com
0.0011) and 36 h (p = 0.0019) for cells subject to Nucleofection®. Solid black bars represen
PA:LFn-GAL4:ASO complex. The antisense effect documented against Synt5 was also directed a
(p = 0.0104) after treatment with the PA:LFn-GAL4:ASO complex (solid white bar) relative to
undifferentiated THP-1 monocytes was investigated (d). Nucleofection®was attempted using
ating knock-down (p = 0.0052). The PA:LFn-GAL4:ASO complex generated signiﬁcant Synt5
complex against differentiated THP-1 macrophages was also investigated (e), and signiﬁcant d
to an untreated control (small squares) was observed (p = 0.0019). A signiﬁcant modulatio
Nucleofection® (solid black bar) (p = b0.0001) relative to the PBS treated control was also rewas investigated. Antisense activity directed against a target gene
(Synt5) was assayed using a HeLa model over 24 h (Fig. 6a). Here,
50 μg of PA and 20 μg of LFn-GAL4were used/mL at each pointmeasured
in a volume of 2 mL. The data was normalized to a housekeeper gene
(EEA1) to control for any variability in cell number and show the
normalized level of Synt5 expression after treatment of the cells
with: (1) media; (2) 200 pmol of nonsense oligonucleotide used with
PA:LFn-GAL4; (3) Nucleofection®; (4) the PA:LFn-GAL4; and
(5) Oligofectamine®. The PA:LFn-GAL4 when added with ASOs,
displayed a pharmacological activity equivalent to Nucleofection® at a
variety of ASO concentrations (24 h post-transfection). In HeLa cells,
at 200 pmol ASO (+PA:LFn-GAL4), 5.4 ± 2.0% Synt5 expression was
recorded relative to an untreated control 24 h after transfection. Using
the same number of oligonucleotides and over the same time frame,
the Nucleofection® system reduced Synt5 expression to 8.1 ± 2.1%
(Fig. 6a). Nucleofection® was performed in 0.1 mL as per the
manufacturer's instructions.
The duration of the antisense effect was also investigated in HeLa
cells (Fig. 6b) using the same transfection conditions i.e. 200 pmol ASO.
Relative to the 0 time point, statistically signiﬁcant down-regulation
of Synt5 was documented using PA:LFn-GAL4:ASO at: 12 h (30.0% ±
14.4) and 24 h (29.5% ± 7.6), and after 12 h (41.6% ± 18), 24 h
(31.2% ± 11.6) and 36 h (55.3% ± 8.2) for cells subject to
Nucleofection® (Fig. 6b).
The antisense effect previously documented against Synt5 was also
directed against an alternate target gene, Human Papilloma Virus sero-
type 18 Early 7 (HPV18 E7) (Fig. 6c) in an initial attempt to demonstrate
both the speciﬁcity and versatility of the described transfection system
as well as to control for the possibility of the delivery system exerting
a non-speciﬁc effect, resulting in target gene down regulation. Aperformed in 0.1 mL for Nucleofection® and 2 mL for Oligofectamine® lipoplex and the
nt5 expression after: 1) PBS treatment (bars containing small squares); 2) a nonsense ol-
:LFn-GAL4:ASO complex (solid white bars); and 5) after treatment with Oligofectamine®
of the Synt5 gene relative to the PBS control were (for the PA:LFn-GAL4:ASO complex):
ucleofection® were: 50 pmol ASO (0.0061), 100 pmol ASO (0.0002) and 200 pmol ASO
mol of ASO was used with either PA:LFn-GAL4 or Nucleofection®. Relative to the 0 time
plex) at 12 h (p = 0.0029) and 24 h (p = 0.0003), and at 12 h (p = 0.0073), 24 h (p =
t cells subject to Nucleofection®, while solid white bars represent cells treated with the
gainst an alternate gene (c) i.e.HPV E7 and shows a signiﬁcant reduction in E7 expression
PBS treated cells (small squares) (24 h). The effect of PA:LFn:GAL4:ASO complex against
200 pmol ASO (solid black bar) and 500 pmol (vertical hatched bar) ASO, the latter medi-
knock-down using 200 pmol of ASO (p = 0.0112). The effect of the PA:LFn-GAL4:ASO
own-regulation of Synt5 expression by the PA:LFn-GAL4:ASO complex (clear bar) relative
n of Synt5 expression by the PA:LFn-GAL4:ASO complex (clear bar) (p = 0.0001) and
corded in Vero cells (f).
Fig. 6 (continued).
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(65.3% ± 4.4) after treatment with the PA:LFn-GAL4:ASO relative to
an untreated control after 24 h.
The ability of PA:LFn-GAL4:ASO to down-regulate a target gene in a
variety of primate cell lines was also undertaken in order to demon-
strate activity in non-HeLa cells. To this end, PA:LFn-GAL4:ASO was
directed against Synt5 using undifferentiated THP-1 monocytes
(Fig. 6d). Separately, Nucleofection® was also attempted using
200 pmol ASO in the same undifferentiated cells. No Synt5 knock-
down was evident after this ﬁrst attempt at Nucleofection®. When the
amount of ASO used was increased to 500 pmol, Synt5 knock-down
was evident (25.3% ± 16.8 of Synt5 remained) after 24 h. This was in
contrast to the PA:LFn-GAL4:ASO complex, which left a signiﬁcantly
smaller amount of detectable Synt5 (35.2% ± 19.1) after treatment
with 200 pmol of ASO after 24 h.
The effect of the Synt5 targeted PA:LFn-GAL4:ASO complex against
differentiated THP-1 macrophages was also investigated (Fig. 6e).
Here, (35.2%±19.1) Synt5 expressionwas documented after treatment
with the PA:LFn-GAL4:ASO complexmade with 200 pmol ASO (relative
to an untreated control). All attempts at the Nucleofection® of differen-
tiated THP-1 cells resulted in a very high degree of cell death, as wouldbe expected when using this transfection recalcitrant cell line [29].
Consequently, in this instance, no transfection was recorded.
The effect of the PA:LFn-GAL4:ASO complex directed against Synt5
in Vero cells was explored (Fig. 6f). Synt5 expression levels in PA:LFn-
GAL4:ASO complex treated cells, relative to an untreated control were
recorded (22.9% ± 6.9) as well as the effect of Nucleofection® using
Synt5 speciﬁc ASOs (16.2% ± 1.7). PA:LFn-GAL4:ASO complex activity
in Vero cells demonstrated functionality in a non-human primate spe-
cies, using a cell line well characterized in our and many other
laboratories.
3.6. PA:LFn-PKR:siRNA mediated Synt5 down-regulation
The ability of the PA:LFn-PKR:siRNA complex to deliver pharmaco-
logically active siRNA was examined (Fig. 7). After 24 h; 8.5 ± 3.4%
Synt5 expression was recorded after treatment with the PA:LFn-
PKR:siRNA complex (containing 200 pmol of Stealth RNAi™ siRNA).
This was measured against the Nucleofection® of siRNA using
200 pmol of Stealth RNAi™ siRNA. Treatment with the PA:LFn-
PKR:siRNA complex resulted in an almost equivalent level of Synt5
expression of Synt5 relative to Nucleofection® (i.e. 4.6 ± 6.1%) using
Fig. 7. PA:LFn-PKR:siRNA mediated Synt5 down-regulation. The ability of the PA:LFn-
PKR:siRNA complex to deliver Stealth RNAi™ siRNA was investigated and no statistical
difference between the ability of the PA:LFn-PKR:siRNA complex to deliver 200 pM
siRNA (horizontal hatching) relative to Nucleofection® (black bar) was evident. Both the
PA:LFn-PKR:siRNA complex (p≤ 0.0001) andNucleofection® (p=0.0001) showed statis-
tically signiﬁcant target gene knock-down inHeLa cells after 24 h relative to the PBS treat-
ed control (bar containing small boxes). A missense control was also used (bar containing
bigger boxes).
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missense Stealth RNAi™ siRNA was also subject to Nucleofection® and
resulted in no measurable reduction in Synt5 levels (Fig. 7).
4. Discussion
The recombinant proteins produced in E. coli were detected at the
predicted molecular weight when measured by Western immunoblot-
ting and reﬂect the success of other groupswho have performed similar
experiments using recombinant protein sequences derived from Atx
[16,17,18,25]. The ability of PA to multimerize in serum was conﬁrmed
when measured by SANS and the ability of PA:LFn-GAL4 and PA:LFn-
PKR to access the cytosol (Figs. 2-5) was conﬁrmed by both subcellular
fractionation and microscopy. During the SANS experiments PA63, the
“activated” form of PA83, was used in its deuterated form for reasons
of contrast and in serum displayed a radius of gyration (Rg) of 7.0 ±
1.0 nm, comparable to the Rg of the heptameric PA pre-pore (PDB acces-
sion number 1TZN). Furthermore, the Rg of deuterated PA63 in PBS was
3.0± 0.5 nm, and representative of monomeric PA83, predicted to have
an Rg of approximately 4.0 nm (PDB accession number 1T6B) (Fig. 2b).
The scattering data revealed a non-Gaussian conformation that indi-
cates that deuterated PA63 had assembled into multimeric annular
structures in serum, which also reﬂects the predicted behavior of PA
protein from the literature, i.e. forms a supramolecular pre-pore approx-
imately 16 × 18 nm (diameter × length) [28]. This observation rein-
forced the likelihood that the recombinant PA protein would have
biological activity similar to its wild type counterpart. These experi-
ments did not have sufﬁcient resolution to differentiate between
heptameric and octameric PA oligomers, though it remains unclear
whether PA octamerization [14] would aid transfection efﬁciency in
this instance. These data indicate that correctly folded recombinant
material had been produced.
Given that oligonucleotide annealing has been documented to initiate
at the 3′ end of the oligonucleotide, one concern associatedwith generat-
ing GAL4:ASO complexes (Fig. 2a)was that antisense activity would dropduring the use of ASO hybrids (Fig. 2c) or after the association of the hy-
brid oligonucleotides with LFn-GAL4 [30]. When tested for antisense ac-
tivity using an in vitro translation assay, beyond 30 pmol of ASO, the
antisense activity of the 21mer tGFP-speciﬁc ASO, the hybrid ASO and
the hybrid in the presence of LFn-GAL4 were equivalent (Fig. 2c). These
data may also have value when considering the controlled release proﬁle
of this system, as the release of the antisense sequencewas not necessary
for efﬁcient antisense activity above 30 pmol ASO (Fig. 2c). Little attention
was given here to the interaction between GAL4 and double stranded
DNA, as this has been well characterized by others [21,30].
Both LFn-GAL4 and LFn-PKR were detected in the cytosol after
subcellular fractionation and microscopy. The subcellular fractionation
data (Fig. 4) served to reinforce the hypothesis that the signal observed
duringmicroscopywas not simply Texas Red®-labeledmaterial binding
non-speciﬁcally to cell plasmamembranewithout being internalized, or
free Texas Red® released from labeled protein (digested in the
endolysosome) staining the cell (Supplemental Fig. 1) or red autoﬂuo-
rescence (Supplemental Fig. 2) [24]. As subcellular fractionation includ-
ed a control containing no PA aswell as an experiment conducted at 0 °C
(to demonstrate the speciﬁcity of the system) (Fig. 4b), in the interests
of brevity, these data are not shown in relation to the microscopy. The
localization of PA to an LBPA positive structures adds further credibility
to the hypothesis that the recombinant PA produced herein is behaving
in a predictable way [9,10], LBPA being a lipid that is critical to the for-
mation of ILVs, to back-fusion and for LF cytosolic translocation [9,10].
Finally, an investigation into the ability of PA:LFn-GAL4:ASO and the
PA: LFn-PKR:siRNA complexes to deliver pharmacologically active ASOs
and siRNA was undertaken. Modulation of target gene expression re-
corded in response to the delivery of both ASOs and siRNA were statis-
tically robust, approximately equivalent to Nucleofection® (Figs. 6 & 7)
and several logsmore potent than lipofection (Fig. 6a) underscoring this
system's high efﬁciency.
Commercially available reference controls (Oligofectamine®
and Nucleofection®) were deliberately chosen as a benchmark in
order to allow the comparison of the system described herein with
other experimental systems, which could also be benchmarked against
Oligofectamine® and Nucleofection®. Nucleofection® is a technology
routinely used for applications requiring very high efﬁciency transfec-
tion i.e. the transfection of libraries and the generation of stable cell
lines (the manufacturers claim 99% transfection success) [31]. Conse-
quently, through observing a pharmacological that is comparable to
Nucleofection® using the Atx-based system described here, we propose
that this new technology also has very high efﬁciency, though this efﬁ-
ciency may be dependent upon PA receptor expression levels. A second
benchmark is documented (Supplemental Fig. 3 &Supplemental
Table 1) where the efﬁciency of the PA:LFn-X systems are compared
with both free ASO or siRNA.
Direct comparisons of the systems deﬁned hereinwith currently rel-
evant delivery technology such as GalNAc conjugated siRNA constructs
are difﬁcult, as the systems described herein have not yet been tested
in vivo. GalNAc conjugated siRNA have been documented to deliver
siRNA to the liver in vivo [32] though themechanism utilized by GalNAc
to access the cytosol remains unclear. The systems described herein are
quite different from this technology, as (1) it is not restricted to tissue
expressing the asialoglycoprotein receptor (i.e. the liver) and (2) in all
probability utilizes a regulated intracellular membrane recyclingmech-
anism (via the PA pore) to facilitate endosomal escape (i.e. ILV back
fusion). As GalNAc contains no pore forming structure, it is unlikely
that it utilizes a similar system.
The membrane stress and speciﬁcity of PA for LFn were controlled
for herein (Supplemental Fig. 4) using cells incubated with both Texas
Red®-labeled BSA (10mg/mL) and PA protein (25 μg/mL), ﬁxed and im-
munostained for the lysosomal marker LAMP1. Unlike Texas Red®-la-
beled LFn-GAL4 or Texas Red®-labeled LFn-PKR no cytosolic Texas
Red®-labeled BSA was evident. This indirect evidence indicates that
ILV back-fusion was, in all probability the most likely system used to
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we have demonstrated the release of ﬂuorescent-labeled Gelonin into
the cytosol using similar methodology (i.e. ﬂuorescence microscopy)
to monitor polymer-mediated membrane perturbation and cytosolic
cargo transfer [33]. Efforts to investigate the role of ILV back-fusion
(more speciﬁcally, a dependence on LBPA andALIX [9] for pharmacolog-
ical activity of both PA:LFn-GAL4:ASO and PA:LFn-PKR:siRNA) are
currently underway.
The pharmacological activity of the Atx-based transfection system
described was shown to be reproducible during studies investigating
ASO time-dependency and propensity to transfect a selection of primate
cell lines (Fig. 6), and (conceptually) via the successful delivery of siRNA
by PA:LFn-PKR (Fig. 7). Given that the HeLa cells used to document the
duration of antisense activity were in an exponential growth phase, it
remains possible that the duration of the observed antisense effect
(Fig. 6b) may well be extended in vivo, though other variables, such
as mRNA and protein abundance and half-life, would also need to
be considered. Differences in mRNA and protein half-life, abundance
and protein-speciﬁc biology may also account for the variation in pro-
tein knockdown observed when Synt5 is contrasted with HPV18 E7
(Fig. 6a & c).
Relative to the delivery of plasmids, the effective delivery of siRNA
and ASOs requires different parameters to be met [34]. Consequently,
the use of smaller (relative to a plasmid) pieces of nucleic acid (i.e.
ASOs) and the absence of polycations [19,20,21] differentiates this
work from that of others. In order to condense and conjugate plasmid
DNA to disarmed toxins, previous studies have used a polycationic
element sometimes described as an “afﬁnity handle” [21]. The lack of
a condensing agent to mediate nuclease protection here is countered
through the use of chemical modiﬁcation within the nucleic acid back-
bone i.e. through the use of phosphorothioate ASOs. Similarly, as ASOs
and siRNAs were being used, a condensing agent to facilitate the
endocytic capture of the PA:LFn-GAL4:ASO or PA:LFn-PKR:siRNA was
not necessary. This was important as previous studies [19,20,21] con-
taining polycationic condensing agents i.e. poly(Lysine) in conjunction
with toxin components may have lent ambiguity to the conclusion
that protein architecture alone was responsible for the translocation of
the nucleic acid cargo over biological barriers. This is due to the possibil-
ity that the toxin-polycation delivery efﬁciency reported, was being
augmented (even indirectly by stressingmembrane) by the polycation.
Here, this possibility has been controlled for (Supplemental Fig. 4).
Condensing agents aside, LFn-GAL4:ASO and LFn-PKR:siRNA size was
still contentious as the literature states that the complexes generated
herein should be too large to go though the internal lumen of the PA
pore, its minimum diameter being approximately 0.6 nm at the phi
clamp [6]. In the wild, LF and EF may undergo a molten globular transi-
tion, losing higher order structure in order to “ratchet” thorough the
internal lumen of the PA pore [6,35]. Given the size of a supramolecular
assembly composed of a pair of ASOs and two LFn-GAL4 molecules, (or
the LFn-PKR:siRNA equivalent) the data presented herein begins to
question the conventional wisdom describing the transition of material
over the PA pore, hinting at the possibility of the pore dilating to allow
the transit of larger material. Equivalently, it is also possible that the at-
tachment of the ASO or Stealth RNAi™ siRNA to LFn served only to bring
nucleic acid into proximal contact with the PA pore interior, facilitating
translocation into the lumen of the ILV [36]. Given the diameter of a
nucleic acid duplex (~2.0 nm) the DNA would be required to “melt” to
pass through the internal lumen of a static PA pore which, like themol-
ten globular transition of LFn-GFP at pH 5.5 may be thermodynamically
improbable [25]. Previous studies also failed to address the question of
how an interpolyelectrolyte complex (typically 100-200 nm) could
“ratchet” through the internal (negatively charged) lumen of the PA
(or similar) pore [6,21].
The scope of polycations to interact withmembranes [37]mediating
toxicity (such as PEI; Table 2), or transfection [38] has been well docu-
mented. It was shown here that there was, under the parametersconducive to transfection, very little in vitro toxicity when either
PA:LFn-GAL4:ASO or PA:LFn-PKR:siRNA were used (Fig. 3), shedding
new light upon the “PEG-dilemma” [2,39]. The ramiﬁcations of this
observation may also stretch beyond toxicity to body distribution and
the ability to transfect tissue currently beyond the reach of established
non-viral delivery technology [1,2]. The body distribution of the PA pro-
tein has been well documented [40,41] and the studies reported here
conﬁrmed that PA:LFn-GAL4 and PA:LFn-PKRhave the potential to de-
liver ASO and siRNA in a variety of different cell types (includingmono-
cytes and macrophages (Fig. 6d & e) as efﬁciently as Nucleofection®.
Consequently, experiments will be designed to establish proof of
concept in speciﬁc disease model in vivo in the future.
In relation to loading capacity, assuming PA forms a heptamer [6],
three LFn molecules associate with it directly, each forming a dimer
with a second LFn-GAL4 molecule binding the ASO hybrid [21,30].
Consequently one discreet PA(7):LFn-GAL4(6):ASO(6) complex has the
capacity, when considered as a static unit, to contain 6 antisense se-
quences. Although the “drug” loading capacity of the PA:LFn-GAL4:ASO
complex is undoubtedly less than that of an IPEC, the lack of toxicity, the
predictable, regulated nature of membrane translation and lack of a net
positive charge (or prevalent hydrophobicity),may serve to counterbal-
ance the efﬁciency of the PA:LFn-GAL4:ASO complex in relation to the
efﬁciency of the Nucleofection® and lipofection systems reported
(Fig. 6). The PA pore may also be able to sustain the delivery of LFn-
fusion molecules over time. Efforts are currently underway to quantify
how many cytosolic ASO molecules can be detected as a function of
delivery in relation to an observed pharmacological effect. This informa-
tion may be critical when considering the variance of PA receptor
density and type in relation to determining the delivery efﬁciency nec-
essary to treat a speciﬁc pathology. Once target mRNA abundance and
protein half-life are considered in the light of delivery efﬁciency, in-
formed decisions about dosemay be possible, further reducing unwant-
ed off-target effects due to an excess of “drug”. Ultimately, this approach
may also allow the precise control over the level of modulation exerted
over target gene expression, in a given cell, tissue type or person.
In contrast to LFn, PA has been documented as not being particularly
immunogenic in Humans [42]. If repeat dosing is required, immunoge-
nicity may be something that needs to be addressed, but is, for the time
being, beyond the remit of this study. If immunogenicity does become a
problem, there are potentially several ways of dealing with it without
compromising the efﬁcacy of the existing anthrax vaccines (that also
contain PA and LF) [42]. One possible solution may be to PEGylate
assemblies of PA:LFn-X:ASO/siRNA.
5. Conclusion
The novel antisense and siRNA delivery technology described
displays high transfection efﬁciency and little toxicity in vitro. As this
cytosolic delivery platform is a departure from conventional charged
or hydrophobic, non-viral drug delivery technology, it is also possible
that it may not be subject to many of the limitations that have thus far
prevented non-viral drug delivery technology from translating into
routinely used clinical tools.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.jconrel.2015.10.054.
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